Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features

• Published in: Journal of cellular biochemistry 2019-05, Vol.120 (5), p.8640-8647
• Main Authors: Heidari, Zahra, Mohammadpour‐Gharehbagh, Abbas, Eskandari, Moein, Harati‐Sadegh, Mahdiyeh, Salimi, Saeedeh
• Format: Article
• Language: English
• Subjects: Gene expression; Gene polymorphism; Gene regulation; Genotype & phenotype; Genotypes; Genotyping; let7a‐2; micro‐RNA (miRNAs); miRNA; Papillary thyroid carcinoma; papillary thyroid carcinoma (PTC); Patients; Polymerase chain reaction; Polymorphism; pri‐mir‐34b/c; Restriction fragment length polymorphism; Risk; Thyroid; Thyroid cancer; Transcription; Tumor suppressor genes
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.28152

microRNAs (miRNAs) as a group of short noncoding RNAs are crucial molecules in transcriptional and translational regulation of oncogenes and tumor suppressor genes. Evidence showed there was an association between the miRNA polymorphisms and various cancers, including papillary thyroid carcinoma (PTC). The present study aims to evaluate the possible effects of let7a‐2 rs1143770 and pri‐mir‐34b/c rs4938723 polymorphisms on PTC susceptibility. A total of 120 patients with PTC and 130 age, sex, and race matched controls were enrolled in the case‐control study. The polymerase chain reaction‐restriction fragment length polymorphism method was used for genotyping of let7a‐2 rs1143770 and pri‐mir‐34b/c rs4938723 polymorphisms. The let7a‐2 rs1143770 CT and TT genotypes were associated with a 1.9‐fold and 2.2‐fold higher risk of PTC, respectively (P = 0.027 and P = 0.041). Moreover, the let7a‐2 rs1143770 polymorphism was associated with increased PTC risk in both dominant (2‐fold, P = 0.015) and the allelic model (1.5‐fold, P = 0.03). The frequency of pri‐mir‐34b/c rs4938723TC genotype was significantly higher in patients with PTC and associated with a two‐fold higher risk of PTC (P = 0.013). In addition, this polymorphism was associated with a 1.8‐fold increased risk of PTC in dominant model (P = 0.021). The let7a‐2 rs1143770CT genotype was associated with a 3.5‐fold increased risk of N1 stage in PTC patients (P = 0.04), however, pri‐mir‐34b/c rs4938723TC genotype was associated with a 3.4‐fold and 5.1‐fold increased risk of III‐IV stage and vascular invasion in PTC group, respectively (P = 0.04 and P = 0.04). In conclusion, the present study shows that let7a‐2 rs1143770 and pri‐mir‐34b/c rs4938723 polymorphisms could be susceptible factors for PTC and some clinical features.